Update on the TGA’s interim decision on MDMA and Psilocybin

05 February 2021
 
 
 

Members may be aware of the recent decision by the Therapeutic Goods Administration (TGA):Notice of interim decisions to amend (or not amend) the current Poisons Standard not to reschedule MDMA and psilocybin from a prohibited substance to a controlled medicine (Schedule 8).

There were numerous public submissions made on this matter with varying positions on the issue, including the College’s submission.

The College supports the TGA’s decision not to amend the Standard in relation to MDMA or psilocybin, and any decision based on evidence-based practice. This decision has been based strongly on the scientific evidence presented in submissions.

We now have the opportunity to affirm our position on this matter in response to the TGA’s interim decision, before the final decision is handed down.

The College remains strongly supportive of appropriate research to assess the efficacy, safety and effectiveness of psychedelic therapies to inform future potential use in psychiatric practice.